Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives

References

• Fishbane S, Spinowitz B. Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018. Am J Kidney Dis. 2018;71(3):423–435. doi:10.1053/j.ajkd.2017.09.02629336855
   PubMed Web of Science ®Google Scholar
• Hazin MAA. Anemia in chronic kidney disease. Rev Assoc Med Bras. 2020;66(Suppl1):s55–s58. doi:10.1590/1806-9282.66.S1.55
   Web of Science ®Google Scholar
• Palmer SC, Saglimbene V, Mavridis D, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2014;(12):CD010590. doi:10.1002/14651858.CD010590.pub225486075
   PubMed Web of Science ®Google Scholar
• Drüeke TB, Massy ZA. Erythropoiesis-stimulating agents and mortality. J Am Soc Nephrol. 2019;30(6):907–908.doi:10.1681/ASN.201903026631015256
   PubMed Web of Science ®Google Scholar
• Sakaguchi Y, Hamano T, Wada A, Masakane I. Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis. J Am Soc Nephrol. 2019;30(6):1037–1048. doi:10.1681/ASN.201810100731015255
   PubMed Web of Science ®Google Scholar
• Goldsmith D, Dellanna F, Schiestl M, Krendyukov A, Combe C. Epoetin biosimilars in the treatment of renal anemia: what have we learned from a decade of european experience? Clin Drug Investig. 2018;38(6):481–490.doi:10.1007/s40261-018-0637-1
   Web of Science ®Google Scholar
• Drüeke TB, Parfrey PS. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int. 2012;82(9):952–960.doi:10.1038/ki.2012.27022854645
   PubMed Web of Science ®Google Scholar
• Kidney Disease Improving global outcomes Anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):279–335. doi:10.1038/kisup.2012.37.
   Google Scholar
• Luo J, Jensen DE, Maroni BJ, Brunelli SM. Spectrum and burden of erythropoiesis-stimulating agent hyporesponsiveness among contemporary hemodialysis patients. Am J Kidney Dis. 2016;68(5):763–771. doi:10.1053/j.ajkd.2016.05.03127528373
   PubMed Web of Science ®Google Scholar
• Santos EJF, Hortegal EV, Serra HO, Lages JS, Salgado-Filho N, Dos Santos AM. Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study. Braz J Med Biol Res. 2018;51(7):e7288. doi:10.1590/1414-431x2018728829742267
   PubMed Web of Science ®Google Scholar
• Gillespie IA, Macdougall IC, Richards S, et al. Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study. Pharmacoepidemiol Drug Saf. 2015;24(4):414–426. doi:10.1002/pds.375525690434
   PubMed Web of Science ®Google Scholar
• Sibbel SP, Koro CE, Brunelli SM, Cobitz AR. Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients. BMC Nephrol. 2015;16:144. doi:10.1186/s12882-015-0138-x26283069
   PubMed Web of Science ®Google Scholar
• Iorember FM. Malnutrition in chronic kidney disease. Front Pediatr. 2018;6:161. doi:10.3389/fped.2018.0016129974043
   PubMed Web of Science ®Google Scholar
• Shah HH, Uppal NN, Fishbane S. Inflammation and erythropoiesis-stimulating agent hyporesponsiveness: a critical connection. Kidney Med. 2020;2(3):245–247. doi:10.1016/j.xkme.2020.05.00132734947
   PubMedGoogle Scholar
• Agarwal N, Prchal JT. Anemia of chronic disease (anemia of inflammation). Acta Haematol. 2009;122(2–3):103–108. doi:10.1159/00024379419907147
   PubMed Web of Science ®Google Scholar
• Bae MN, Kim SH, Kim YO, et al. Association of erythropoietin-stimulating agent responsiveness with mortality in hemodialysis and peritoneal dialysis patients. PLoS One. 2015;10(11):e0143348. doi:10.1371/journal.pone.014334826588085
   PubMed Web of Science ®Google Scholar
• Badve SV, Beller EM, Cass A, et al. Interventions for erythropoietin-resistant anaemia in dialysis patients. Cochrane Database Syst Rev. 2013;(8):CD006861. doi:10.1002/14651858.CD006861.pub323979995
   PubMed Web of Science ®Google Scholar
• Karaboyas A, Morgenstern H, Fleischer NL, et al. Inflammation and erythropoiesis-stimulating agent response in hemodialysis patients: a self-matched longitudinal study of anemia management in the dialysis outcomes and practice patterns study (DOPPS). Kidney Med. 2020;2(3):286–296. doi:10.1016/j.xkme.2020.01.00732734248
   PubMedGoogle Scholar
• Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol. 2017;18(1):345. doi:10.1186/s12882-017-0688-129191165
   PubMed Web of Science ®Google Scholar
• Aoun M, Karam R, Sleilaty G, Antoun L, Ammar W, Barretti P. Iron deficiency across chronic kidney disease stages: is there a reverse gender pattern? PLoS One. 2018;13(1):e0191541. doi:10.1371/journal.pone.019154129357391
   PubMed Web of Science ®Google Scholar
• Li X, Cole SR, Kshirsagar AV, Fine JP, Stürmer T, Brookhart MA. Safety of dynamic intravenous iron administration strategies in hemodialysis patients. Clin J Am Soc Nephrol. 2019;14(5):728–737. doi:10.2215/CJN.0397031830988164
   PubMed Web of Science ®Google Scholar
• Gupta J, Mitra N, Kanetsky PA, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012;7(12):1938–1946.doi:10.2215/CJN.0350041223024164
   PubMed Web of Science ®Google Scholar
• Cobo G, Lindholm B, Stenvinkel P. Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant. 2018;33(suppl_3):iii35–iii40. doi:10.1093/ndt/gfy17530281126
   PubMed Web of Science ®Google Scholar
• Vianna HR, Soares CMBM, Tavares MS, Teixeira MM, Silva ACSE. Inflamação na doença renal crônica: papel de citocinas. [Inflammation in chronic kidney disease: the role of cytokines]. J Bras Nefrol. 2011;33(3):351–364.doi:10.1590/s0101-2800201100030001222042353
   PubMedGoogle Scholar
• Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2002;17(Suppl suppl_11):39–43.doi:10.1093/ndt/17.suppl_11.39
   Web of Science ®Google Scholar
• Minoo P, Zadeh MM, Rottapel R, Lebrun -J-J, Ali S. A novel SHP-1/Grb2-dependent mechanism of negative regulation of cytokine-receptor signaling: contribution of SHP-1 C-terminal tyrosines in cytokine signaling. Blood. 2004;103(4):1398–1407.doi:10.1182/blood-2003-07-261714551136
   PubMed Web of Science ®Google Scholar
• Rao M, Wong C, Kanetsky P, et al. Cytokine gene polymorphism and progression of renal and cardiovascular diseases. Kidney Int. 2007;72(5):549–556. doi:10.1038/sj.ki.500239117579660
   PubMed Web of Science ®Google Scholar
• Sanghani NS, Haase VH. Hypoxia-inducible factor activators in renal anemia: current clinical experience. Adv Chronic Kidney Dis. 2019;26(4):253–266. doi:10.1053/j.ackd.2019.04.00431477256
   PubMed Web of Science ®Google Scholar
• Zha Y, Qian Q. Protein nutrition and malnutrition in CKD and ESRD. Nutrients. 2017;9(3):208. doi:10.3390/nu9030208
   PubMed Web of Science ®Google Scholar
• González-Ortiz A, Correa-Rotter R, Vázquez-Rangel A, Vega-Vega O, Espinosa-Cuevas Á. Relationship between protein-energy wasting in adults with chronic hemodialysis and the response to treatment with erythropoietin. BMC Nephrol. 2019;20(1):316. doi:10.1186/s12882-019-1457-031412807
   PubMed Web of Science ®Google Scholar
• Jankowska M, Rutkowski B, Dębska-Ślizień A. Vitamins and microelement bioavailability in different stages of chronic kidney disease. Nutrients. 2017;9(3):282.doi:10.3390/nu9030282
   Web of Science ®Google Scholar
• Alves MT, Vilaça SS, Carvalho M, Fernandes AP, Dusse LMSA, Gomes KB. Resistance of dialyzed patients to erythropoietin. Rev Bras Hematol Hemoter. 2015;37(3):190–197. doi:10.1016/j.bjhh.2015.02.00126041422
   PubMedGoogle Scholar
• Rattanasompattikul M, Molnar MZ, Zaritsky JJ, et al. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant. 2013;28(7):1936–1945. doi:10.1093/ndt/gfs36823045431
   PubMed Web of Science ®Google Scholar
• Roger SD, Locatelli F, Woitas RP, et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant. 2011;26(12):3980–3986. doi:10.1093/ndt/gfr16021505096
   PubMed Web of Science ®Google Scholar
• Wright M, Southcott E, MacLaughlin H, Wineberg S. Clinical practice guideline on undernutrition in chronic kidney disease. BMC Nephrol. 2019;20(1):370.doi:10.1186/s12882-019-1530-831619185
   PubMed Web of Science ®Google Scholar
• Mizobuchi M, Ogata H, Koiwa F. Secondary hyperparathyroidism: pathogenesis and latest treatment. Ther Apher Dial. 2018;23(4):309–318. doi:10.1111/1744-9987.1277230411503
   PubMed Web of Science ®Google Scholar
• Komaba H, Kakuta T, Fukagawa M. Management of secondary hyperparathyroidism: how and why? Clin Exp Nephrol. 2017;21(Suppl S1):37–45. doi:10.1007/s10157-016-1369-228044233
   PubMed Web of Science ®Google Scholar
• Tanaka M, Komaba H, Fukagawa M. Emerging association between parathyroid hormone and anemia in hemodialysis patients. Ther Apher Dial. 2018;22(3):242–245. doi:10.1111/1744-9987.1268529767854
   PubMed Web of Science ®Google Scholar
• Tanaka M, Yoshida K, Fukuma S, et al. Effects of secondary hyperparathyroidism treatment on improvement in anemia: results from the MBD-5D study. PLoS One. 2016;11(10):e0164865. doi:10.1371/journal.pone.016486527764168
   PubMed Web of Science ®Google Scholar
• Samavat S, Nafar M, Khoshdel A, Alipour-Abedi B. Factors contributing to erythropoietin hyporesponsiveness among hemodialysis patients: a cross-sectional multicenter study. Nephrourol Mon. 2017;In Press(In Press). doi:10.5812/numonthly.45003
   Google Scholar
• Kiss Z, Ambrus C, Kulcsár I, Szegedi J, Kiss I. Effect of angiotensin-converting enzyme gene insertion/deletion polymorphism and angiotensin-converting enzyme inhibition on erythropoiesis in patients on haemodialysis. J Renin Angiotensin Aldosterone Syst. 2015;16(4):1021–1027.doi:10.1177/147032031453527625002133
   PubMed Web of Science ®Google Scholar
• Maeda A, Tsuruya K, Maeda M, et al. Hemodialysis treatment time versus erythropoietin dose requirement: reduction in 2000 units per week by extension of hemodialysis for 1 hour. Clin Nephrol. 2019;92(4):174–179.doi:10.5414/CN10940331272526
   PubMed Web of Science ®Google Scholar
• Mercadal L, Coudert M, Vassault A, et al. L-carnitine treatment in incident hemodialysis patients: the multicenter, randomized, double-blinded, placebo-controlled CARNIDIAL trial. Clin J Am Soc Nephrol. 2012;7(11):1836–1842.doi:10.2215/CJN.1243121122935844
   PubMed Web of Science ®Google Scholar
• Higuchi T. Effects of levocarnitine on cardiac function and renal anemia in hemodialysis patients. Contrib Nephrol. 2018;196:96–100.doi:10.1159/00048570630041211
   PubMed Web of Science ®Google Scholar
• Kang DW, Ahn CY, Ryu BK, Shin BC, Chung JH, Kim HL. The effect of intravenous ascorbic acid in hemodialysis patients with normoferritinemic anemia. Kidney Res Clin Pract. 2012;31(1):48–53.doi:10.1016/j.krcp.2012.01.00226889408
   PubMedGoogle Scholar
• Nand N, Deshmukh AR, Mittal R. Evaluation of effect of ascorbic acid on ferritin and erythropoietin resistance in patients of chronic kidney disease. J Assoc Physicians India. 2017;65(7):32–36.
   Google Scholar
• Nand N, Mittal R. Evaluation of effect of vitamin D deficiency on anemia and erythropoietin hyporesponsiveness in patients of chronic kidney disease. J Assoc Physicians India. 2017;65(2):38–42.
   Google Scholar
• Icardi A, Paoletti E, Nicola L, Mazzaferro S, Russo R, Cozzolino M. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrol Dial Transplant. 2013;28(7):1672–1679.doi:10.1093/ndt/gft02123468534
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Abe M, Okada K, et al. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis. Nutrients. 2015;7(5):3783–3795.doi:10.3390/nu705378325988769
   PubMed Web of Science ®Google Scholar
• Thomas A, Peterson LE. Reduction of costs for anemia-management drugs associated with the use of ferric citrate. Int J Nephrol Renovasc Dis. 2014;2014(default):191–201.
   Google Scholar
• Saifan C, Samarneh M, Shtaynberg N, Nasr R, El-Charabaty E, El-Sayegh S. Treatment of confirmed B12 deficiency in hemodialysis patients improves Epogen® requirements. Int J Nephrol Renovasc Dis. 2013;2013(default):89–93.doi:10.2147/IJNRD.S44660
   Google Scholar